Tynifer Capsule contains Ferric Maltol, an oral iron preparation used to treat iron deficiency in adults. It is formulated to deliver iron efficiently through the gastrointestinal tract, helping restore depleted iron stores while maintaining good tolerability.
Treatment of iron deficiency in adults
Ferric Maltol delivers iron in a stable complex that allows uptake across the intestinal wall and transfer to iron-binding proteins such as transferrin and ferritin. Clinical studies have shown that ferric maltol increases key serum iron parameters, including ferritin levels and transferrin saturation (TSAT), thereby correcting iron deficiency.
রেজিস্টার্ড চিকিৎসকের পরামর্শ অনুযায়ী ঔষধ সেবন করুন
Route of administration: Oral
Recommended dose: 30 mg twice daily
Administration instructions:
Take preferably on an empty stomach, at least 1 hour before or 2 hours after meals
Do not open, break, or chew the capsule
Duration of treatment:
Depends on the severity of iron deficiency
Generally, a minimum of 12 weeks is required
Continue treatment until ferritin levels return to the normal range
Pediatric use:
Safety and effectiveness have not been established in pediatric patients
Concomitant use with dimercaprol may increase the risk of nephrotoxicity; avoid combined use
May reduce the bioavailability of certain drugs, including:
Mycophenolate
Ethynyl estradiol
Ciprofloxacin
Doxycycline
For drugs where reduced absorption may affect safety or efficacy, administer Tynifer at least 4 hours apart
Food reduces the bioavailability of iron when taken with Tynifer
Known hypersensitivity to ferric maltol or any component of the formulation
History of hemochromatosis or other iron overload syndromes
Patients receiving repeated blood transfusions
Commonly reported side effects include:
Flatulence
Diarrhea
Constipation
Discoloration of feces
Abdominal pain
Nausea and vomiting
Ferric maltol is not absorbed systemically as an intact complex after oral administration.
Pregnancy: Maternal use is not expected to result in fetal exposure
Lactation: Breastfeeding is not expected to expose the infant to ferric maltol
There are no data on its presence in human milk or effects on milk production.
Avoid use in patients with an active inflammatory bowel disease flare due to potential gastrointestinal inflammation
Do not administer to patients with iron overload or those receiving intravenous iron
Assess iron parameters before starting treatment and monitor during therapy
Accidental overdose of iron-containing products can be fatal in children under 6 years of age
In case of accidental overdose, seek immediate medical attention
No specific data are available on overdose with Tynifer. Early symptoms may include nausea, vomiting, abdominal pain, and diarrhea. Severe cases may lead to hypoperfusion, metabolic acidosis, systemic toxicity, and iron accumulation in storage sites, potentially resulting in hemosiderosis.
Oral iron preparations
Store in a cool and dry place below 25°C
Protect from light
Keep out of reach of children.
Login Or Registerto submit your questions to seller
No none asked to seller yet